{"id":"targeted-systemic-therapy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297595","moleculeType":"Small molecule","molecularWeight":"515.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a broad category descriptor rather than a specific drug, referring to systemic cancer therapies that employ targeting strategies such as antibody-drug conjugates, receptor-targeted small molecules, or immunotherapies. The exact mechanism depends on the specific therapeutic agent being developed, but generally involves binding to tumor-associated antigens or pathways and delivering cytotoxic effects preferentially to cancer cells.","oneSentence":"Targeted Systemic Therapy is a cancer treatment designed to selectively target and destroy malignant cells while minimizing damage to healthy tissue.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:53:49.286Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indication unknown)"}]},"trialDetails":[{"nctId":"NCT07495566","phase":"","title":"Inflammatory Markers in Lumbar Radicular Pain Treated With PRF and TFESI","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2025-12-30","conditions":"Inflammatory Response, Radiculopathy, Radiculopathy Lumbar","enrollment":264},{"nctId":"NCT04998682","phase":"NA","title":"Prospective Evaluation of Targeted Axillary Dissection (TAD)","status":"COMPLETED","sponsor":"University of Miami","startDate":"2022-03-01","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT07493395","phase":"PHASE2","title":"Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-04-01","conditions":"Scleroderma, Systemic","enrollment":6},{"nctId":"NCT07151690","phase":"PHASE2","title":"BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-04","conditions":"Systemic Light Chain Amyloidosis","enrollment":21},{"nctId":"NCT07426094","phase":"PHASE2, PHASE3","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","status":"RECRUITING","sponsor":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","startDate":"2026-03-19","conditions":"Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT)","enrollment":1600},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT06150651","phase":"PHASE1","title":"Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-12-01","conditions":"SLE (Systemic Lupus)","enrollment":3},{"nctId":"NCT06713798","phase":"PHASE2","title":"Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures","status":"WITHDRAWN","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-01-30","conditions":"Metastatic Cancer Lung, Advanced Lung Cancer, CBNPC Cancer","enrollment":""},{"nctId":"NCT07001748","phase":"PHASE2, PHASE3","title":"Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2025-08-19","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis","enrollment":148},{"nctId":"NCT07334002","phase":"NA","title":"The Effects of Conventional Therapy on Tinnitus, Disability, and Quality of Life in Patients With Tinnitus","status":"NOT_YET_RECRUITING","sponsor":"Sisli Hamidiye Etfal Training and Research Hospital","startDate":"2026-03-01","conditions":"Tinnitus, Neural Therapy of Huneke","enrollment":30},{"nctId":"NCT07487675","phase":"PHASE2","title":"Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc Displacement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tanta University","startDate":"2024-09-29","conditions":"Temporomandibular Joint Internal Derangement (ADWR)","enrollment":10},{"nctId":"NCT06738160","phase":"PHASE2","title":"The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-02-15","conditions":"NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy","enrollment":27},{"nctId":"NCT07484932","phase":"NA","title":"TRTRM (ACTTOP) -Guided Dosing Strategy in Older Patients With Cancer","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-05-01","conditions":"Cancer (Solid Tumors), Geriatric Oncology","enrollment":400},{"nctId":"NCT07124078","phase":"PHASE2","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2026-03-31","conditions":"Chronic Graft-versus-host-disease","enrollment":60},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT04710576","phase":"PHASE2","title":"A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Syndax Pharmaceuticals","startDate":"2021-03-04","conditions":"Chronic Graft-versus-host-disease","enrollment":241},{"nctId":"NCT07469072","phase":"PHASE2","title":"Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)","status":"NOT_YET_RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2026-02-25","conditions":"Continuous Renal Replacement Therapy (CRRT)","enrollment":92},{"nctId":"NCT07467590","phase":"PHASE2","title":"Combination of High and Low-Dose Radiotherapy With Immune Therapy and TKI in Advanced Colorectal Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-04-01","conditions":"Refractory Colorectal Cancer, Radiotherapy-Induced Immune Priming, Immune Response","enrollment":33},{"nctId":"NCT07463248","phase":"PHASE2","title":"PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy","status":"NOT_YET_RECRUITING","sponsor":"Wang Xin","startDate":"2026-03-05","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":64},{"nctId":"NCT07461961","phase":"PHASE2","title":"CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-07-01","conditions":"Cardiogenic Shock, Heart Failure, Inflammation","enrollment":30},{"nctId":"NCT06427798","phase":"PHASE1, PHASE2","title":"Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-07","conditions":"Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma","enrollment":66},{"nctId":"NCT05660408","phase":"PHASE1, PHASE2","title":"RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2025-03-12","conditions":"Recurrent Pulmonary Osteosarcoma, Recurrent High-grade Glioma","enrollment":36},{"nctId":"NCT06308978","phase":"PHASE1","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-03-28","conditions":"Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc)","enrollment":244},{"nctId":"NCT07459127","phase":"","title":"Multicenter Retrospective Cohort of Pulmonary NUT Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Three Gorges Hospital of Chongqing University","startDate":"2023-01-01","conditions":"NUT Carcinoma","enrollment":150},{"nctId":"NCT07457632","phase":"PHASE2","title":"Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine.","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Diabetic Macular Edema (DME)","enrollment":69},{"nctId":"NCT07458620","phase":"PHASE1","title":"Prospective Single-Arm Safety Study of Cervical LVA in AD Patients","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-03","conditions":"Alzheimer's Disease (AD)","enrollment":35},{"nctId":"NCT07453329","phase":"NA","title":"Assessment of Functional Outcomes of Custom-made Articulating Spacers in Two Stage Arthroplasty for Treatment of Infected Hip Joint","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-10-31","conditions":"Arthoplasty, Infected Hernioplasty Mesh, PJI","enrollment":25},{"nctId":"NCT07448363","phase":"","title":"Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica","status":"NOT_YET_RECRUITING","sponsor":"Caja Costarricense de Seguro Social","startDate":"2026-05","conditions":"Atopic Dermatitis, Atopic Dermatitis (AD), Atopic Dermatitis (Eczema)","enrollment":50},{"nctId":"NCT07115745","phase":"PHASE1","title":"A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-09-04","conditions":"Refractory Autoimmune Diseases","enrollment":125},{"nctId":"NCT07442110","phase":"","title":"This Observational Study Evaluates the Clinical Outcomes of Patients With Diabetes Who Utilize a Specialized Dietary Supplements for Foot Ulcer Healing. The Study Documents the Rate of Complete Wound Closure and the Prevention of Lower Extremity Amputations in a Real-world, At-home Setting.","status":"COMPLETED","sponsor":"Amar h Zireg","startDate":"2025-07-05","conditions":"Limb Salvage, Diabetes Complication, Dietary Supplements","enrollment":35},{"nctId":"NCT06813664","phase":"PHASE2","title":"ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-04-01","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease","enrollment":60},{"nctId":"NCT06897930","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-21","conditions":"Lupus Erythematosus, Systemic","enrollment":150},{"nctId":"NCT06797713","phase":"NA","title":"Effect of Targeted Fluid Therapy on Postoperative Cognitive Dysfunction.","status":"COMPLETED","sponsor":"TC Erciyes University","startDate":"2025-07-01","conditions":"Cognitive Dysfunction, Postoperative","enrollment":60},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT07444307","phase":"PHASE1","title":"A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Hangzhou Qihan Biotech Co., Ltd.","startDate":"2025-12-15","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":18},{"nctId":"NCT07053085","phase":"PHASE2","title":"A Study of Surgery and Radiotherapy in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-09-17","conditions":"Metastatic Breast Cancer, HER2-positive Breast Cancer","enrollment":162},{"nctId":"NCT03808337","phase":"PHASE2","title":"Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-01-16","conditions":"Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer","enrollment":145},{"nctId":"NCT07432334","phase":"PHASE1","title":"CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"Vinmec Research Institute of Stem Cell and Gene Technology","startDate":"2026-03-01","conditions":"Refractory Systemic Lupus Erythematosus","enrollment":8},{"nctId":"NCT07422948","phase":"NA","title":"Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-02-05","conditions":"Acute on Chronic Liver Failure","enrollment":113},{"nctId":"NCT07419867","phase":"PHASE2","title":"A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT05534321","phase":"PHASE1, PHASE2","title":"Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2022-08-29","conditions":"Spine Metastases","enrollment":74},{"nctId":"NCT06384560","phase":"PHASE1, PHASE2","title":"Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)","status":"RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2024-09-23","conditions":"Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma","enrollment":66},{"nctId":"NCT07406646","phase":"NA","title":"Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1)","status":"COMPLETED","sponsor":"Institute of Oncology Ljubljana","startDate":"2021-11-02","conditions":"Renal Cell Carcinoma, Advanced Kidney Cancer","enrollment":91},{"nctId":"NCT06459427","phase":"NA","title":"A Multicenter, RAndomIzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With AI-assisted Robotic guidanCe for Hemorrhagic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Yu","startDate":"2026-04","conditions":"Brain Stem Hemorrhage, Robotic Surgical Procedures","enrollment":142},{"nctId":"NCT07403097","phase":"PHASE1","title":"Study of CD19 CAR-T Therapy for Refractory SLE","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2026-02","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT06991920","phase":"NA","title":"Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-06-30","conditions":"Adult ALL, MPAL","enrollment":50},{"nctId":"NCT07295847","phase":"PHASE1","title":"A Study of AZD0120 in Autoimmune Diseases","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-09","conditions":"Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis","enrollment":27},{"nctId":"NCT07255638","phase":"","title":"A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany","status":"RECRUITING","sponsor":"Blueprint Medicines Corporation","startDate":"2025-12-09","conditions":"Indolent Systemic Mastocytosis","enrollment":80},{"nctId":"NCT06992661","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With Interstitial Lung Disease","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-01-15","conditions":"Interstitial Lung Disease (ILD), Healthy Volunteers","enrollment":84},{"nctId":"NCT07010835","phase":"PHASE1, PHASE2","title":"Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Excyte Biopharma Ltd","startDate":"2025-08-25","conditions":"Systemic Lupus Erythematosus (SLE)","enrollment":189},{"nctId":"NCT07201519","phase":"PHASE2","title":"Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","status":"RECRUITING","sponsor":"Michael J Cavnar, MD","startDate":"2026-01-23","conditions":"Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma","enrollment":80},{"nctId":"NCT06222853","phase":"PHASE1","title":"Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-02-10","conditions":"Systemic Lupus Erythematosus, CAR-T Cell Therapy","enrollment":22},{"nctId":"NCT07085104","phase":"PHASE1","title":"A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease","status":"RECRUITING","sponsor":"Allogene Therapeutics","startDate":"2025-11-13","conditions":"Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy, Systemic Sclerosis","enrollment":54},{"nctId":"NCT07305116","phase":"PHASE1","title":"CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2025-12-01","conditions":"Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), Multi-Drug Resistant Nephrotic Syndrome","enrollment":15},{"nctId":"NCT07318259","phase":"PHASE1","title":"Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2026-01-26","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT06486181","phase":"PHASE4","title":"Second Line Endovascular Treatment in Acute DVT","status":"NOT_YET_RECRUITING","sponsor":"Rush University Medical Center","startDate":"2026-04-01","conditions":"Deep Venous Thrombosis","enrollment":100},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT06323473","phase":"PHASE2","title":"Maitake for Integrative Cancer Care","status":"RECRUITING","sponsor":"The Canadian College of Naturopathic Medicine","startDate":"2024-10-15","conditions":"Cancer","enrollment":40},{"nctId":"NCT04928261","phase":"PHASE4","title":"Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-12-13","conditions":"Breast Cancer","enrollment":52},{"nctId":"NCT07358988","phase":"PHASE1","title":"KN5501 Cell Injection for Refractory SLE(CLEAR)","status":"NOT_YET_RECRUITING","sponsor":"Ruitherapeutics Co., LTD","startDate":"2026-01","conditions":"Systemic Lupus Erthematosus (SLE)","enrollment":36},{"nctId":"NCT06468280","phase":"PHASE2","title":"Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-11-08","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":84},{"nctId":"NCT06481813","phase":"NA","title":"Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2024-12-10","conditions":"Lung Cancer, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":730},{"nctId":"NCT07353827","phase":"PHASE2","title":"FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy","enrollment":36},{"nctId":"NCT06726421","phase":"PHASE3","title":"Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-18","conditions":"Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma Metastatic","enrollment":252},{"nctId":"NCT07335770","phase":"","title":"Cardiac Magnetic Resonance for Diagnosis, Treatment Guidance and Prognosis of Cardiac Masses (CMR)","status":"ENROLLING_BY_INVITATION","sponsor":"Minjie Lu","startDate":"2008-01-01","conditions":"Cardiac Masses","enrollment":2000},{"nctId":"NCT07335237","phase":"PHASE2","title":"Clinical Study on the Prevention and Treatment of Postoperative Gastrointestinal Dysfunction by Acupuncture Under ERAS Management Based on Artificial Intelligence Monitoring","status":"COMPLETED","sponsor":"Jiangsu Province Hospital of Traditional Chinese Medicine","startDate":"2022-09-01","conditions":"Colectomy, Colectomy Left/Right/Total Under Laparotomy, Cancer","enrollment":70},{"nctId":"NCT07335887","phase":"PHASE2","title":"Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":"AL Amyloidosis (AL), t(11;14) Positive","enrollment":39},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT07331467","phase":"PHASE1","title":"Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2026-01","conditions":"Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT07333664","phase":"PHASE2","title":"Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Metastatic Solid Tumors","enrollment":120},{"nctId":"NCT07333651","phase":"PHASE2","title":"125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Oligometastatic Disease","enrollment":90},{"nctId":"NCT06620380","phase":"PHASE2","title":"Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2025-09-12","conditions":"Brain Metastases, Brain Metastases, Adult","enrollment":102},{"nctId":"NCT07330856","phase":"PHASE4","title":"Evaluation of Treatments for Dry or Productive Cough","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2026-01-19","conditions":"Cough","enrollment":58},{"nctId":"NCT04591574","phase":"NA","title":"ABC - A Post Intensive Care Anaemia Management Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Edinburgh","startDate":"2020-09-01","conditions":"Anemia Acute, Fatigue, Physical Disability","enrollment":346},{"nctId":"NCT06255028","phase":"PHASE1","title":"A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Century Therapeutics, Inc.","startDate":"2025-02-06","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies","enrollment":6},{"nctId":"NCT03782207","phase":"","title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-02-07","conditions":"Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer","enrollment":2756},{"nctId":"NCT04989803","phase":"PHASE1, PHASE2","title":"Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2021-10-27","conditions":"Relapsed and/or Refractory B-cell Lymphoma","enrollment":247},{"nctId":"NCT07321847","phase":"PHASE2, PHASE3","title":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Immunophotonics, Inc.","startDate":"2026-05","conditions":"Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer","enrollment":717},{"nctId":"NCT07266116","phase":"PHASE1, PHASE2","title":"Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients","status":"RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-12-26","conditions":"Systemic Light Chain Amyloidosis","enrollment":70},{"nctId":"NCT05717166","phase":"PHASE3","title":"A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.","status":"RECRUITING","sponsor":"David Palma","startDate":"2023-10-06","conditions":"Metastatic Tumor","enrollment":180},{"nctId":"NCT07310719","phase":"NA","title":"A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital","status":"RECRUITING","sponsor":"Lagos State Health Service Commission","startDate":"2025-10-15","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":138},{"nctId":"NCT00255346","phase":"PHASE2","title":"Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-11-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia","enrollment":68},{"nctId":"NCT06842316","phase":"","title":"Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2025-04-10","conditions":"Inflammatory Disorder of Immune System, Spondylitis, Ankylosing, Arthritis, Rheumatoid","enrollment":100},{"nctId":"NCT07309952","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Yang Hong","startDate":"2025-12-31","conditions":"Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT07304271","phase":"PHASE3","title":"Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Magnus Nilsson","startDate":"2025-11-05","conditions":"Gastric Cancer Peritoneal Metastases","enrollment":262},{"nctId":"NCT06530849","phase":"PHASE1","title":"A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Gracell Biotechnologies (Shanghai) Co., Ltd.","startDate":"2024-08-22","conditions":"Refractory Systemic Lupus Erythematosus","enrollment":18},{"nctId":"NCT07079462","phase":"PHASE2","title":"Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilimab Versus Second-Line Standard Therapy in Colorectal Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET","enrollment":40},{"nctId":"NCT04965766","phase":"PHASE2","title":"Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2021-05-11","conditions":"Metastatic Breast Cancer, Advanced Breast Cancer","enrollment":139},{"nctId":"NCT06892145","phase":"PHASE1","title":"Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2025-06-12","conditions":"Systemic Lupus Erythematosus (SLE), Refractory","enrollment":12},{"nctId":"NCT06792344","phase":"PHASE1","title":"Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2024-12-15","conditions":"Systemic Sclerosis (SSc)","enrollment":12},{"nctId":"NCT03610711","phase":"PHASE1, PHASE2","title":"REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-03-06","conditions":"Gastroesophageal Cancer, Immune Checkpoint Inhibition","enrollment":21},{"nctId":"NCT05465343","phase":"PHASE2","title":"Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)","status":"COMPLETED","sponsor":"Peking Union Medical College","startDate":"2022-07-11","conditions":"Furmonertinib, EGFR-mutation, NSCLC","enrollment":24},{"nctId":"NCT02314182","phase":"PHASE3","title":"GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2014-11-20","conditions":"Rectal Adenocarcinoma","enrollment":5},{"nctId":"NCT06498154","phase":"PHASE2","title":"Eliminating Breast Surgery for Breast Cancer Patients With Clinical Complete Response to Neoadjuvant Systemic Therapy","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-25","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT05860296","phase":"PHASE1, PHASE2","title":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","status":"TERMINATED","sponsor":"SignalChem Lifesciences Corporation","startDate":"2023-05-31","conditions":"Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, Lung Cancer Metastatic","enrollment":36},{"nctId":"NCT07285434","phase":"EARLY_PHASE1","title":"Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"NSCLC (Non-small Cell Lung Cancer), Squamous Lung Cancer With FGFR1 Amplification, Non-Squamous Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT07276555","phase":"NA","title":"Efficacy and Safety of Functional Neurogenesis Stimulation Therapy in Children With Autism Spectrum Disorder (ASD)","status":"NOT_YET_RECRUITING","sponsor":"Neurocytonix, Inc.","startDate":"2026-02-01","conditions":"Autism Spectrum Disorder","enrollment":256}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":103,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Targeted Systemic Therapy","genericName":"Targeted Systemic Therapy","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Targeted Systemic Therapy is a cancer treatment designed to selectively target and destroy malignant cells while minimizing damage to healthy tissue. Used for Cancer (specific indication unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}